Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
2024; Elsevier BV; Volume: 25; Issue: 6 Linguagem: Inglês
10.1016/s1470-2045(24)00178-5
ISSN1474-5488
AutoresAndrea Necchi, M. Roumiguié, Ashish M. Kamat, Neal D. Shore, Joost L. Boormans, Adil Esen, Thierry Lebrét, Shuya Kandori, Dean F. Bajorin, Laurence E. Krieger, Scot A. Niglio, Edward Uchio, Ho Kyung Seo, Ronald de Wit, Eric A. Singer, Petros Grivas, Hyeong Dong Yuk, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish S. Kulkarni,
Tópico(s)Epigenetics and DNA Methylation
ResumoThe KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. In cohort A (patients with carcinoma in situ, with or without papillary tumours) of the KEYNOTE-057 study, pembrolizumab monotherapy led to a complete response rate of 41% at 3 months, and 46% of responders maintained a response lasting at least 12 months. Here, we evaluate pembrolizumab monotherapy in cohort B of patients with papillary tumours without carcinoma in situ.
Referência(s)